Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03332576 · ClinicalTrials.gov registry record · Phase 1
Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
A Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.).
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 3
- Study locations
NCT03332576: Completed Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.).
NCT03332576 is a Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer that has completed, run by ImmunoVaccine Technologies, Inc. (IMV Inc.). The registered enrollment target is 37 participants, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03332576, a Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, has completed, sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 3
- Study locations
Study Summary
As a follow-on study to NCT01416038, this study is designed to identify the optimal dosage of immunotherapeutic survivin vaccine DPX-Survivac and low dose oral cyclophosphamide. The combination treatment is being evaluated in a non-randomized, multi-cohort study as post-chemotherapy treatment for patients with late-stage ovarian, fallopian tube, or peritoneal cancer.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL DPX-Survivac
- BIOLOGICAL DPX-Survivac(Aqueous)
Study Locations (3)
New York
- Winthrop University Hospital - Mineola
- Lenox Hill Hospital - New York
Ontario
- Princess Margaret Cancer Centre - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2013-08-23 |
| Est. Completion | 2019-09-09 |
| Phase | Phase 1 |
What the finished NCT03332576 record still lists
NCT03332576 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (85% lower).
The record links to 3 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT03332576 reports a single indexed study location in New York, Ontario.
Frequently Asked Questions
What is clinical trial NCT03332576 about?
NCT03332576 is a clinical study titled "Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer". As a follow-on study to NCT01416038, this study is designed to identify the optimal dosage of immunotherapeutic survivin vaccine DPX-Survivac and low dose oral cyclophosphamide. The combination treatment is being evaluated in a non-randomized, multi-cohort study as post-chemotherapy treatment for pa...
What is the current status of trial NCT03332576?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2013-08-23. Estimated completion is 2019-09-09.
What conditions does trial NCT03332576 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Epithelial Ovarian Cancer, Peritoneal Cancer.
What interventions are being tested in trial NCT03332576?
The interventions under investigation include: Cyclophosphamide (DRUG), DPX-Survivac (BIOLOGICAL), DPX-Survivac(Aqueous) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03332576?
This trial is sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.), which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03332576 being conducted?
This trial has 3 study locations across New York, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03332576's enrollment target sits among peer trials
37 56th of 85 higher than 30 of 85 other Fallopian Tube Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fallopian Tube Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 1
-
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
RECRUITING · Phase 1
-
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
RECRUITING · Phase 1
-
A Study of ZN-c3 in Patients With Ovarian Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI